CELGENE CORPORATION (NASDAQ:CELG) Files An 8-K Results of Operations and Financial ConditionITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On July27, 2017, Celgene Corporation issued a press release announcing its financial results for its fiscal quarter ended June30, 2017. A copy of this press release is attached hereto as Exhibit99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form8-K, the information in this Current Report on Form8-K, including Exhibit99.1, that is furnished to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d)Exhibit99.1 Press Release dated July27, 2017 announcing results for the quarter ended June30, 2017.
This exhibit is furnished to Item 2.02 and shall not be deemed to be “filed.”
CELGENE CORP /DE/ ExhibitEX-99.1 2 a17-18490_1ex99d1.htm EX-99.1 Exhibit 99.1 Contacts: Investors: Media: Patrick E. Flanigan III Brian P. Gill Corporate Vice President Vice President Investor Relations Corporate Communications (908) 673-9969 (908) 673-9530 CELGENE REPORTS SECOND QUARTER 2017 OPERATING AND FINANCIAL RESULTS · Strong Q2 performance; Updated 2017 EPS guidance · Positive ozanimod phase III data in relapsing multiple sclerosis (RMS) advances neuroscience franchise opportunities · Completed enrollment in five phase III trials during Q2,…To view the full exhibit click here
About CELGENE CORPORATION (NASDAQ:CELG)
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.